Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807973 | 0.85 | ESR1 (0.40) | ESR1ESR2GRIA4ALOX5HDAC8 | |
| SCHEMBL6803409 | 0.77 | ALDH1A1 (0.53) | RARB | |
| SCHEMBL12608892 | 0.76 | ESR1 (0.48) | ESR1ESR2CYP2D6CHRM1ADRA1A | |
| SCHEMBL21005024 | 0.75 | CYP2D6 (0.70) | CYP2D6PTGS2LMNA | |
| SCHEMBL20511280 | 0.75 | CYP2D6 (0.70) | CYP2D6PTGS2LMNA | |
| SCHEMBL23903947 | 0.75 | CYP2D6 (0.70) | CYP2D6PTGS2LMNA | |
| SCHEMBL20511263 | 0.75 | CYP2D6 (0.70) | CYP2D6PTGS2LMNA | |
| SCHEMBL20511261 | 0.75 | CYP2D6 (0.70) | CYP2D6PTGS2LMNA | |
| SCHEMBL11822535 | 0.75 | CYP2D6 (0.70) | CYP2D6PTGS2LMNA | |
| SCHEMBL16816897 | 0.71 | CYP2D6 (0.57) | CYP2D6LMNAPOLBMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063959-A1 | Esters and amides as PLA2 inhibitors | FUKAMI NAOKI (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 2002-11-14 | — | — | US | disclosed |
| EP-0854863-B1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-10-30 | — | — | EP | disclosed |
| US-20020019416-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-14 | — | — | US | disclosed |
| EP-0854863-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997003951-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063959-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | ESR1 3294/4885ESR2 2712/4885CYP2D6 647/4885 |
| US-20020019416-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | PLA2G4A, PLA2G4B, PLA2G1B | ESR1 3114/4885ESR2 2768/4885CYP2D6 761/4885 |
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | ESR1 3279/4885ESR2 2706/4885CYP2D6 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.